___

• Kaynaklar 1.Asher MI, Montefort S, Björksten B, Lai CK, Strachan DP, Wei-land SK, et al. Worldwide time trends in the prevalence ofsymptoms of asthma, allergic rhinoconjunctivitis, and eczema inchildhood: ISAAC Phases One and Three repeat multicountrycross-sectional surveys. Lancet. 2006;368:733-43. 2.Ait-Khaled N, Odhiambo J, Pearce N, Adjoh KS, Maesano IA, Ben-habyles B, et al. Prevalence of symptoms of asthma, rhinitis andeczema in 13- to 14-year-old children in Africa: the Internatio-nal Study of Asthma and Allergies in Childhood Phase III. Allergy.2007;62(3):247-58. 3.Bousquet, J, Lockey R..F, Malling H.J WHO position paper. Al-lergen immunotherapy: therapeutic vaccines for allergic disea-ses. Allergy. 1998;53, 1-42 4.Cox L. Allergen immunotherapy and asthma: efficacy, safety, andother considerations. Allergy Asthma Proc. 2008;29(6):580-9.doi: 10.2500/aap.2008.29.3162. 5.Cox L, Li J., Lockey F, Richard L. Allergen immunotherapy: Apractice parameter second update. J Allergy Clin Immunol.2007;120:25-85. 6.Bernstein DI, Wanner M, Borish L, Liss GM; ImmunotherapyCommittee, American Academy of Allergy, Asthma and Immuno-logy. Twelve-year survey of fatal reactions to allergen injectionsand skin testing: 1990-2001. J Allergy Clin Immunol.2004;113(6):1129-36. 7.Bousquet J., Lockey R., Malling H.J ve ark. Allergen immunot-herapy: Therapeutic vaccines for allergic diseases. World healthOrganisation .American Academy of Allergy, Asthma and Immu-nology. Annals of Allergy Asthma and Immunology. 1998;81,401-405. 8.Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Dur-ham S. Allergen injection immunotherapy for seasonal allergicrhinitis. Cochrane Database Syst Rev. 2007;(1):CD001936. 9.Passalaqua G, Durham SR. Allergic rhinitis and its impact on asth-ma update: allergen immunotherapy. Journal of Allergy and Cli-nical Immunology. 2007;119, 881-891. 10.Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunothe-rapy Study Group. [Efficacy and safety of specific immunothe-rapy with SQ allergen extract in treatment-resistant seasonal al-lergic rhinoconjunctivitis]. J Allergy Clin Immunol.2006;117(2):319-25. 11.Powell RJ, Frew A.J., Corrigan CJ, et al. Effect of grass pollenimmunotherapy with Durham Sr,Alutard SQ on quality of life inseasonal allergic rhinoconjunctivitis. Allergy 2007;62, 1335-1338. 12.Abramson M., Puy R., Weiner J.M. (1995) Is allergen immunot-herapy effective in asthma? A meta-analysis of randomized con-trolled trials. American Journal of Respiratory and Critical CareMedicine. 151, 969-974 13.Abramson MJ, Puy RM, Weiner JM. [Injection allergen immu-notherapy for asthma]. Cochrane Database Syst Rev. 2010 Aug4;(8):CD001186. doi: 10.1002/14651858.CD001186.pub2. 14.Wilson DR, Lima MT, Durham SR. [Sublingual immunotherapyfor allergic rhinitis: systematic review and meta-analysis]. Al-lergy. 2005;60(1):4-12. 15.Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE,Orozco S, Pedroza A, et al. [Metaanalysis of the efficacy of sub-lingual immunotherapy in the treatment of allergic asthma in pe-diatric patients, 3 to 18 years of age]. Chest. 2008;133(3):599-609. 16.Calamita Z, Saconato H, Pelá AB, Atallah AN. [Efficacy of sub-lingual immunotherapy in asthma: systematic review of rando-mized-clinical trials using the Cochrane Collaboration method].Allergy. 2006;61(10):1162-72. 17.Bufe A. [Usefulness of sublingual immunotherapy in children.Drugs Today (Barc)]. 2008;44 Suppl B:61-3. 18.Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, FrischerT, Götz M, et al. [Diagnosis and treatment of asthma in child-hood: a PRACTALL consensus report]. Allergy. 2008;63(1):5-34. 19.Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Hu-erta J, Passalacqua G, et al. [Efficacy of sublingual immunothe-rapy in the treatment of allergic rhinitis in pediatric patients 3to 18 years of age: a meta-analysis of randomized, placebo-con-trolled, double-blind trials]. Ann Allergy Asthma Immunol.2006;97(2):141-8. 20.Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Gal-vain S, et al. [Sublingual-swallow immunotherapy (SLIT) with astandardized five-grass-pollen extract (drops and sublingual tab-lets) versus placebo in seasonal rhinitis]. Allergy. 1999;54(8):819-28. 21.La Rosa M, Ranno C, André C, Carat F, Tosca MA, CanonicaGW. [Double-blind placebo-controlled evaluation of sublingu-al-swallow immunotherapy with standardized Parietaria judai-ca extract in children with allergic rhinoconjunctivitis]. J AllergyClin Immunol. 1999;104:425-32. 22.Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. [Sub-lingual immunotherapy with once-daily grass allergen tablets:a randomized controlled trial in seasonal allergic rhinoconjunc-tivitis]. J Allergy Clin Immunol. 2006;117(4):802-9. 23.Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, EmmingerW, et al. [Efficacy and safety of sublingual immunotherapy withgrass allergen tablets for seasonal allergic rhinoconjunctivitis].J Allergy Clin Immunol. 2006;118(2):434-40. 24.Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Kli-mek L, et al. [Safety and efficacy in children of an SQ-standar-dized grass allergen tablet for sublingual immunotherapy]. J Al-lergy Clin Immunol. 2009;123(1):167-173.e7. doi:10.1016/j.jaci.2008.10.044. 25.Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A,et al. [Optimal dose, efficacy, and safety of once-daily sublingu-al immunotherapy with a 5-grass pollen tablet for seasonal al-lergic rhinitis]. J Allergy Clin Immunol. 2007;120(6):1338-45. 26.Dahl R, Stender A, Rak S. [Specific immunotherapy with SQ stan-dardized grass allergen tablets in asthmatics with rhinoconjunc-tivitis]. Allergy. 2006;61(2):185-90. 27.Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. [Clini-cal and immunologic effects of sublingual immunotherapy in asth-matic children sensitized to mites: a double-blind, randomized,placebo-controlled study]. Pediatr Allergy Immunol.2006;17(6):408-15. 28.Pham-Thi N1, Scheinmann P, Fadel R, Combebias A, Andre C.[Assessment of sublingual immunotherapy efficacy in children withhouse dust mite-induced allergic asthma optimally controlled bypharmacologic treatment and mite-avoidance measures]. Pedi-atr Allergy Immunol. 2007;18(1):47-57. 29.Moreno-Ancillo A, Moreno C, Ojeda P, Domínguez C, Baraso na MJ, García-Cubillana A, et al. [Efficacy and quality of life withonce-daily sublingual immunotherapy with grasses plus olive pol-len extract without updosing]. J Investig Allergol Clin Immunol.2007;17(6):399-405. 30.Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, NelsonHS. [Response to sublingual immunotherapy with grass pollenextract: monotherapy versus combination in a multiallergen ext-ract]. J Allergy Clin Immunol. 2009;124(1):150-156.e1-5. doi:10.1016/j.jaci.2009.04.037. 31.Malling H. [Position paper: Immunotherapy with hymenopteravenoms. (EAACI) The European Academy of Allergology and Cli-nical Immunology]. Allergy. 1993;48(14 Suppl):36-46. 32.Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. [Im-munotherapy with a standardized Dermatophagoides pteronys-sinus extract. Systemic reactions during the rush protocol in pa-tients suffering from asthma]. J Allergy Clin Immunol.1989;83(4):797-802. 33.Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacob-son M, et al. [Grass pollen sublingual immunotherapy for sea-sonal rhinoconjunctivitis: a randomized controlled trial]. Clin ExpAllergy. 2002;32(4):507-14. 34.Alvarez-Cuesta E, Berges-Gimeno P, González-Mancebo E, Fer-nández-Caldas E, Cuesta-Herranz J, Casanovas M. [Sublingu-al immunotherapy with a standardized cat dander extract: eva-luation of efficacy in a double blind placebo controlled study].Allergy. 2007;62(7):810-7. 35.Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I,Nelson HS. [Sublingual immunotherapy: a comprehensive revi-ew]. J Allergy Clin Immunol. 2006;117(5):1021-35. 36.Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. [Anaphy-laxis to sublingual immunotherapy]. Allergy. 2006Oct;61(10):1235. 37.Eifan AO, Keles S, Bahceciler NN, Barlan IB. [Anaphylaxis tomultiple pollen allergen sublingual immunotherapy]. Allergy.2007;62(5):567-8. 38.Blazowski L. [Anaphylactic shock because of sublingual immu-notherapy overdose during third year of maintenance dose. Al-lergy]. 2008;63(3):374. 39.Windom HH, Lockey RF. [An update on the safety of specific im-munotherapy]. Curr Opin Allergy Clin Immunol. 2008;8(6):571-6. doi: 10.1097/ACI.0b013e32831845fb. 40.Galip N, Bahceciler N. [Rare adverse events due to house dustmite sublingual immunotherapy in pediatric practice: two casereports]. Immunotherapy. 2015;7(12):1235-9. doi:10.2217/imt.15.88. 41.Flicker S, Steinberger P, Norderhaug L, Sperr WR, Majlesi Y, Va-lent P, et al. [Conversion of grass pollen allergen-specific humanIgE into a protective IgG(1) antibody]. Eur J Immunol.2002;32(8):2156-62. 42.van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Niel-sen A, Arnved J, e t al. [Blocking antibodies induced by specificallergy vaccination prevent the activation of CD4+ T cells by in-hibiting serum-IgE-facilitated allergen presentation]. J Immunol. 1999;163 (5):29 44 -52. 43.Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M,Blaser K, et al. [IL-10 and TGF-beta cooperate in the regulatoryT cell response to mucosal allergens in normal immunity and spe-cific immunotherapy]. Eur J Immunol. 2003;33(5):1205-14. 44.Akdis CA., Blesken T, Akdis M, Wüthrich B, Blaser K. [Role ofinterleukin 10 in specific immunotherapy]. J Clin Invest. 1998;102(1): 98–106. doi: 10.1172/JCI2250. 45.Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, Proud D, Me-ier HL, Naclerio RM, et al. [Nasal challenge with ragweed pol-len in hay fever patients. Effect of immunotherapy]. J Clin Invest.1985;76(6):2247-53. 46.Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M.[Changes in nasal metachromatic cells during allergen immunot-herapy]. Clin Exp Allergy 1991;21:115–119. 47.Marcucci F, Incorvaia C, Sensi L, Di Cara G, Cadario G, Ca-valiere A, et al. [Lack of inflammatory cells in the oral mucosaof subjects undergoing sublingual immunotherapy]. Int J Immu-nopathol Pharmacol. 2008;21(3):609-13. 48.Bagnasco M, Altrinetti V, Pesce G, Caputo M, Mistrello G, Fa-lagiani P, et al. [Pharmacokinetics of Der p 2 allergen and de-rived monomeric allergoid in allergic volunteers]. Int Arch Al-lergy Immunol. 2005;138(3):197-202. 49.Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Bo-rini E, et al. [Pharmacokinetics of an allergen and a monome-ric allergoid for oromucosal immunotherapy in allergic volun-teers]. Clin Exp Allergy. 2001;31(1):54-60. 50.Nouri-Aria KT1, Wachholz PA, Francis JN, Jacobson MR, Wal-ker SM, Wilcock LK, et al. [Grass pollen immunotherapy indu-ces mucosal and peripheral IL-10 responses and blocking IgGactivity]. J Immunol. 2004;172(5):3252-9. 51.Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR.[Grass pollen immunotherapy: efficacy and safety during a 4-yearfollow-up study]. Allergy. 1995;50(5):405-13. 52.Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canoni-ca GW, Chapman MD, et al. [Allergen immunotherapy: thera-peutic vaccines for allergic diseases. World Health Organizati-on. American academy of Allergy, Asthma and Immunology]. AnnAllergy Asthma Immunol. 1998;81(5):401-5. 53.Allam JP, Peng WM, Appel T, Wenghoefer M, Niederhagen B,Bieber T, et al. [Toll-like receptor 4 ligation enforces toleroge-nic properties of oral mucosal Langerhans cells]. J Allergy ClinImmunol. 2008;121(2):368-374.e1. 54.Allam JP, Klein E, Bieber T, Novak N. [Transforming growth fac-tor-beta1 regulates the expression of the high-affinity receptorfor IgE on CD34 stem cell-derived CD1a dendritic cells in vit-ro]. J Invest Dermatol. 2004;123(4):676-82. 55.Bahceciler NN, Galip N. [Comparing subcutaneous and sublin-gual ımmunotherapy: what do we know?]. Curr Opin Allergy ClinImmunol. 2012;12(6):640-7. doi: 10. 1097/ ACI.0b013e328358d5f2. 56.Durham SR, Penagos M. [Sublingual or subcutaneous immunot-herapy for allergic rhinitis?]. J Allergy Clin Immunol.2016;137(2):339-349.e10. doi: 10.1016/j.jaci.2015.12.1298. 57.Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S,Høst A, et al. [Specific immunotherapy has long-term preventi-ve effect of seasonal and perennial asthma: 10-year follow-up onthe PAT study]. Allergy. 2007;62(8):943-8. 58.Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. [Twelve-yearfollow-up after discontinuation of preseasonal grass pollen immu-notherapy in childhood]. Allergy. 2006;61(2):198-201.59.Durham SR; GT-08 investigators. [Sustained effects of grass pol-len AIT]. Allergy. 2011 Jul;66 Suppl 95:50-2. doi: 10.1111/j.1398-9995.2011.02639.x. 60.Marogna M, Spadolini I, Massolo A, Canonica GW, Passalac-qua G. [Long-lasting effects of sublingual immunotherapy accor-ding to its duration: a 15-year prospective study]. J Allergy ClinImmunol. 2010;126(5):969-75. doi: 10.1016/j. jaci.2010.08.030.